Loading...
Header Logo
Keywords
Last Name
Institution

Camille Gunderson

Concepts (201)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Genital Neoplasms, Female
8
2018
70
4.620
Why?
Ovarian Neoplasms
13
2018
415
3.980
Why?
Poly(ADP-ribose) Polymerase Inhibitors
4
2018
20
2.400
Why?
Uterine Neoplasms
4
2016
57
2.170
Why?
Neoplasms, Glandular and Epithelial
4
2017
78
1.760
Why?
Retrospective Studies
18
2018
1585
1.630
Why?
Female
35
2018
10316
1.510
Why?
Aged, 80 and over
15
2018
1514
1.480
Why?
Aged
22
2018
3736
1.450
Why?
Middle Aged
24
2018
5151
1.390
Why?
Neoplasm Recurrence, Local
4
2018
290
1.380
Why?
Antineoplastic Agents
6
2018
630
1.310
Why?
Laparoscopy
5
2016
119
1.300
Why?
Vaginal Neoplasms
2
2013
11
1.280
Why?
Adult
22
2018
5346
1.280
Why?
Endometrial Hyperplasia
2
2013
7
1.240
Why?
Hysterectomy
5
2016
69
1.230
Why?
Health Services Accessibility
2
2013
77
1.180
Why?
Patient Selection
3
2018
140
1.180
Why?
Humans
35
2018
18523
1.140
Why?
Endometrial Neoplasms
2
2013
117
1.130
Why?
Clinical Trials as Topic
3
2017
136
1.120
Why?
Obesity
2
2016
360
1.060
Why?
Healthcare Disparities
2
2018
61
1.040
Why?
Carcinoma, Endometrioid
3
2017
37
1.040
Why?
Precision Medicine
2
2018
29
0.970
Why?
Cystadenocarcinoma, Serous
2
2016
28
0.960
Why?
Neutropenia
3
2018
31
0.900
Why?
Clinical Trials, Phase I as Topic
1
2018
15
0.890
Why?
Phthalazines
2
2015
13
0.880
Why?
Piperazines
2
2015
34
0.870
Why?
Antineoplastic Agents, Immunological
1
2018
17
0.860
Why?
Patient Participation
1
2017
34
0.820
Why?
Leiomyomatosis
1
2016
3
0.790
Why?
Vascular Neoplasms
1
2016
4
0.790
Why?
Vena Cava, Inferior
1
2016
14
0.780
Why?
Angiogenesis Inhibitors
1
2018
112
0.780
Why?
Intensive Care Units
1
2016
28
0.770
Why?
Progestins
2
2013
7
0.750
Why?
Genes, BRCA1
1
2015
9
0.750
Why?
Genes, BRCA2
1
2015
10
0.750
Why?
Muscle, Smooth, Vascular
1
2016
78
0.740
Why?
Germ-Line Mutation
1
2015
19
0.740
Why?
Genetic Testing
1
2015
37
0.720
Why?
Uterine Cervical Neoplasms
2
2016
203
0.690
Why?
Sarcoma
1
2014
25
0.660
Why?
Hospitals, High-Volume
1
2013
7
0.650
Why?
Surgery Department, Hospital
1
2013
9
0.650
Why?
Adolescent
8
2017
2240
0.640
Why?
Inflammation
1
2016
315
0.640
Why?
Enzyme Inhibitors
1
2015
242
0.630
Why?
Insurance, Health
1
2013
55
0.620
Why?
Prognosis
6
2016
621
0.620
Why?
Carcinoma
1
2014
77
0.620
Why?
Young Adult
7
2018
1821
0.620
Why?
Venous Thromboembolism
1
2014
77
0.610
Why?
Ambulatory Care
1
2013
60
0.610
Why?
Carcinoma in Situ
1
2013
38
0.610
Why?
Adenocarcinoma, Clear Cell
3
2016
15
0.600
Why?
Hospitalization
1
2013
111
0.590
Why?
Fertility Preservation
1
2012
3
0.590
Why?
Mutation
1
2016
645
0.580
Why?
Genital Diseases, Female
1
2011
1
0.580
Why?
Antineoplastic Agents, Hormonal
1
2012
21
0.580
Why?
Hernia, Umbilical
1
2011
4
0.580
Why?
Neoplasm Staging
6
2016
479
0.570
Why?
Pregnancy Outcome
1
2012
70
0.550
Why?
Age Factors
4
2018
525
0.550
Why?
Follow-Up Studies
5
2016
810
0.540
Why?
Risk Factors
5
2016
1455
0.530
Why?
Postoperative Complications
1
2014
369
0.510
Why?
Gynecologic Surgical Procedures
1
2010
38
0.510
Why?
Treatment Outcome
6
2015
1615
0.480
Why?
Adenocarcinoma
1
2012
278
0.460
Why?
Disease-Free Survival
4
2017
282
0.450
Why?
Lung Transplantation
1
2008
2
0.450
Why?
Enterocolitis, Pseudomembranous
1
2008
16
0.440
Why?
Survival Rate
4
2017
377
0.430
Why?
Cytoreduction Surgical Procedures
2
2017
18
0.420
Why?
Clostridium difficile
1
2008
52
0.410
Why?
Neoplasms, Cystic, Mucinous, and Serous
2
2017
12
0.410
Why?
Molecular Targeted Therapy
2
2018
64
0.390
Why?
Image Processing, Computer-Assisted
2
2018
169
0.380
Why?
Poly(ADP-ribose) Polymerases
2
2015
23
0.360
Why?
Randomized Controlled Trials as Topic
2
2015
187
0.340
Why?
Proportional Hazards Models
2
2014
163
0.330
Why?
Ovariectomy
2
2016
36
0.330
Why?
Risk Assessment
2
2018
421
0.330
Why?
Body Mass Index
2
2016
293
0.320
Why?
Chemotherapy, Adjuvant
3
2017
100
0.310
Why?
Neoadjuvant Therapy
2
2017
33
0.260
Why?
Kaplan-Meier Estimate
3
2016
167
0.250
Why?
Neoplasm Grading
3
2016
89
0.250
Why?
Oklahoma
2
2014
854
0.250
Why?
Cohort Studies
2
2018
622
0.230
Why?
Health Equity
1
2018
1
0.230
Why?
Proteinuria
1
2018
7
0.220
Why?
Epistaxis
1
2018
5
0.220
Why?
Nausea
1
2018
10
0.220
Why?
Vomiting
1
2018
10
0.220
Why?
Water-Electrolyte Imbalance
1
2018
5
0.220
Why?
Headache
1
2018
17
0.220
Why?
Intestinal Perforation
1
2018
12
0.220
Why?
Anemia
1
2018
22
0.220
Why?
Fatigue
1
2018
30
0.220
Why?
Bevacizumab
1
2018
61
0.220
Why?
Diarrhea
1
2018
48
0.220
Why?
Sulfonamides
1
2018
43
0.210
Why?
Image Interpretation, Computer-Assisted
1
2018
118
0.200
Why?
Pyrimidines
1
2018
90
0.200
Why?
Hemorrhage
1
2018
131
0.200
Why?
Carcinosarcoma
1
2016
16
0.200
Why?
Autoimmune Diseases
1
2018
131
0.200
Why?
Antineoplastic Combined Chemotherapy Protocols
2
2017
306
0.200
Why?
Syndrome
1
2016
59
0.200
Why?
Intimate Partner Violence
1
2016
2
0.190
Why?
Hypertension
1
2018
214
0.190
Why?
Lymph Node Excision
1
2016
107
0.180
Why?
Early Detection of Cancer
1
2016
87
0.180
Why?
Poly (ADP-Ribose) Polymerase-1
1
2015
5
0.180
Why?
Pilot Projects
1
2016
232
0.180
Why?
Genomics
1
2016
94
0.180
Why?
Clinical Trials, Phase II as Topic
1
2015
17
0.180
Why?
Cross-Sectional Studies
2
2016
527
0.180
Why?
Patient Acceptance of Health Care
1
2016
63
0.180
Why?
Lymph Nodes
1
2016
113
0.180
Why?
Drug Evaluation, Preclinical
1
2015
50
0.180
Why?
Diagnosis, Differential
1
2016
310
0.180
Why?
Administration, Oral
1
2015
121
0.170
Why?
Thrombophlebitis
1
2014
4
0.170
Why?
Palliative Care
1
2015
63
0.170
Why?
Receptors, Progesterone
1
2013
13
0.170
Why?
Postoperative Care
1
2014
51
0.170
Why?
Preoperative Care
1
2014
59
0.170
Why?
Receptors, Estrogen
1
2013
19
0.160
Why?
Histocytochemistry
1
2013
22
0.160
Why?
Quality of Life
1
2016
257
0.160
Why?
Health Facilities
1
2013
5
0.160
Why?
Tomography, X-Ray Computed
1
2017
430
0.160
Why?
Overweight
1
2014
72
0.160
Why?
Demography
1
2013
82
0.160
Why?
Length of Stay
1
2014
164
0.160
Why?
Academic Medical Centers
1
2013
58
0.160
Why?
Surgical Wound Infection
1
2014
67
0.160
Why?
Multivariate Analysis
1
2014
266
0.160
Why?
Fever
1
2013
33
0.160
Why?
Ablation Techniques
1
2013
14
0.160
Why?
Papanicolaou Test
1
2013
27
0.160
Why?
Continental Population Groups
1
2013
85
0.160
Why?
Vaginal Smears
1
2013
40
0.150
Why?
Vagina
1
2013
28
0.150
Why?
Breast Neoplasms
1
2018
409
0.150
Why?
Survival Analysis
1
2013
254
0.150
Why?
Ethnic Groups
1
2013
118
0.150
Why?
Brain Neoplasms
1
2015
188
0.150
Why?
Combined Modality Therapy
1
2013
276
0.140
Why?
Salpingectomy
1
2011
6
0.140
Why?
Predictive Value of Tests
1
2013
379
0.140
Why?
Severity of Illness Index
1
2013
317
0.140
Why?
Disease Progression
1
2013
320
0.140
Why?
Uterus
1
2011
21
0.140
Why?
Practice Patterns, Physicians'
1
2013
167
0.140
Why?
European Continental Ancestry Group
1
2013
435
0.130
Why?
African Americans
1
2013
348
0.130
Why?
Robotics
1
2010
46
0.130
Why?
Endoscopy
1
2010
56
0.130
Why?
Anti-Bacterial Agents
1
2013
302
0.120
Why?
Time Factors
1
2014
1165
0.120
Why?
Pregnancy
1
2012
608
0.120
Why?
Bronchiolitis Obliterans
1
2008
2
0.110
Why?
Graft Rejection
1
2008
27
0.110
Why?
Incidence
1
2008
401
0.100
Why?
Child
1
2008
1542
0.070
Why?
Animals
1
2015
6945
0.070
Why?
Tissue Array Analysis
1
2018
34
0.060
Why?
Area Under Curve
1
2018
79
0.060
Why?
Cluster Analysis
1
2018
118
0.060
Why?
Evidence-Based Practice
1
2018
24
0.060
Why?
Medical Oncology
1
2018
40
0.050
Why?
Gynecology
1
2018
32
0.050
Why?
Vulnerable Populations
1
2018
26
0.050
Why?
Databases, Factual
1
2018
165
0.050
Why?
Platinum Compounds
1
2017
9
0.050
Why?
Neoplasm, Residual
1
2017
30
0.050
Why?
ROC Curve
1
2017
112
0.050
Why?
Peripheral Nervous System Diseases
1
2017
18
0.050
Why?
Platinum
1
2016
23
0.050
Why?
Taxoids
1
2017
40
0.050
Why?
Laparotomy
1
2016
28
0.050
Why?
Organoplatinum Compounds
1
2016
28
0.050
Why?
Ohio
1
2016
11
0.050
Why?
Thrombocytopenia
1
2017
92
0.050
Why?
Hospice Care
1
2015
8
0.050
Why?
Lymphatic Metastasis
1
2016
173
0.050
Why?
Drug Resistance, Neoplasm
1
2016
105
0.050
Why?
Radiotherapy, Adjuvant
1
2015
68
0.040
Why?
Decision Support Techniques
1
2015
41
0.040
Why?
Radiosurgery
1
2015
38
0.040
Why?
Male
1
2008
9340
0.040
Why?
Surveys and Questionnaires
1
2016
625
0.040
Why?
United States
1
2018
1660
0.040
Why?
Gunderson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_